Endogenous and synthetic cannabinoids: Recent advances

CNS Drug Reviews

Volumn 2, Issue 4, 1996, Pages 429-451

  Shohami, Esther ^a   Weidenfeld, Joseph ^a   Ovadia, Haim ^a   Vogel, Zvi ^b   Hanuš, Lumir ^a   Fride, Ester ^a   Breuer, Aviva ^a   Ben Shabat, Shimon ^a   Sheskin, Tzviel ^a   Mechoulam, Raphael ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

2 Arachidonoyl glycerol; Anandamide; Cannabinoid receptors; Head trauma; HU 210; HU 211 9 Tetrahydrocannabinol

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ANTIOXIDANT; CANNABINOID; DEXANABINOL; N METHYL DEXTRO ASPARTIC ACID; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN ISCHEMIA; CATALEPSY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEMORY; MOOD; NEUROPROTECTION; NONHUMAN; SEDATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 12644253801     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00310.x     Document Type: Article

References (136)

1. Askari A, Xie Z, Wang Y, Periyasamy S, Huang WH. A second messenger role for monoacylglycerols is suggested by their activating effects on the sodium pump. Biochim Biophys Acta 1991;1069:127-130.
2. Bar-Joseph A, Berkovitch Y, Adamchik J, Biegon A. Neuroprotective activity of HU-211: A novel NMDA antagonist, in global ischemia in gerbils. Mol Chem Neuropathol 1994;23:125-135.
3. Bass R, Trembovler V, Engelhard D, Shohami E. A novel non-psychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J Inf Dis 1996;173:735-738.
4. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z. The peripheral cannabinoid receptor: Adenylate cyclase inhibition and G protein coupling. FEBS Lett 1995;375:143-147.
5. Bayewitch M, Rhee RH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z. (-)-Delta(9)-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 1996;271:9902-9905.
6. Belayev L, Bar-Joseph A, Adamchik J, Biegon A. HU-211, a non-psychotropic cannabinoid, improves neurological signs and reduces brain damage, after severe forebrain ischemia in rats. Mol Chem Neuropathol 1995;25:19-33.
7. Belayev L, Busto R, Watson B, Ginsberg MD. Post-ischemic administration of HU-211, a novel noncompetitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats: A quantitative study. Brain Res 1995;702:266-270.
8. Bell MR, D'Ambra TE, Kumar V, et al. Antinociceptive (aminoalkyl) indoles. J Med Chem 1991;34:1099-1110.
9. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984;43:1369-1374.
10. 3. J Cereb Blood Flow Metab 1989;9:629-639.
11. Blatteis CM, Hunter WS, Llanos QJ, Ahokas RA, Mashburn TA Jr. Activation of acute phase responses by intrapreoptic injections of endogenous pyrogen in guinea pigs. Brain Res Bull 1984;12:689-695.
12. Cabral GA, Toney DM, Fischer-Stenger K, Harrison MP, Marciano-Cabral F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 1995;56:2065-2072.
13. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 1996;16:3934-3942.
14. Chapman KD, Lin I, DeSouza AD. Metabolism of cottonseed microsomal N-acylphosphatidylethanolamine. Arch Biochem Biophys 1995;2:401-407.
15. Childers SR, Sexton T, Roy MB. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 1994;47:711-715.
16. Choi DW. NMDA receptors and AMPA/kainate receptors mediate parallel injury in cerebral cortical cultures subjected to oxygen-glucose deprivation, in: Kogure K, Hossmann A, Siesjo BK, eds. Progress in Brain Res. Amsterdam: Elsevier, 1993:137-143.
17. 1 gamma-aminobutyric acid synapses and the effect of anandamide. Proc Natl Acad Sci USA 1995;92:10167-10171.
18. Compton DR, Rice KC, De Costa BR, et al. Cannabinoid structure activity relationships: correlation of receptor binding and in vivo activities. J Pharm Exp Ther 1992;265:218-226.
19. Coupar IM, Taylor DA. Alterations in the level of endogenous hypothalamic prostaglandins induced by delta-9-tetrahydrocannabinol in the rat. Br J Pharmacol 1982;76: 115-119.
20. Cox B, Lomax P. Pharmacologic control of temperature regulation. Ann Rev Pharmacol Toxicol 1977;17:341-353.
21. Das SK, Paria BC, Chakraborty I, Dey SK. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci USA 1995;92:4332-4336.
22. Davies JA, Graham DP. The mechanism of action of Δ-9-tetrahydrocannabinol on body temperature in mice. Psychopharmacology 1980;69:299-305.
23. Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 1995;270:6030-6035.
24. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993;46:791-796.
25. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Hewlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613.
26. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
27. Dewey WL, Peng TC, Harris LS. The effect of 1-trans-delta-9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. Eur J Pharmacol 1970;12:382-384.
28. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;38:151-178.
29. Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'Killing two birds with one stone.' Prostag Leuk Ess Fatty Acids 1995;53:1-11.
30. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686-691.
31. Di Marzo V, De Petrocellis L, Bisogno T, Maurelli S. Pharmacology and physiology of the endogenous cannabimimetic mediator anandamide. J Drug Dev Clin Pract 1995;7:199-219.
32. Diemer NH, Valente E, Bruhn T, Berg M, Jorgensen MB, Johansen FF. Glutamate receptor transmission and ischemic nerve cell damage: Evidence for involvement of excitotoxic mechanism, in: Kogure K, Hossman KA, Siesjo BK, eds. Progress in Brain Res. Amsterdam: Elsevier 1993:105-123.
33. Dinarello CA. Interleukins, tumor necrosis factors (cachectin), and interferons as endogenous pyrogens and mediators of fever. In: Pick E, Landy M, eds. Lymphokines. New York: Academic Press, 1987:1-31.
34. Eisenstat MA, Bell MR, D'Ambra TE, et al. (Aminoalkyl) indoles: Structure activity relationships of novel cannabinoid mimetics. J Med Chem 1995;38:3094-3105.
35. Eldridge JC, Landfield PW. Cannabinoids interaction with glucocorticoid receptors in rat hippocampus. Brain Res 1990;534:135-141.
36. Ellis EF, Moore SF, Willoughby KA. Anandamide and delta-(9)-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol Heart and Circul Physiol 1995;38: H1859-H1864.
37. Eshhar N, Streim S, Biegon A. HU-211, a non-psychotropic cannabinoid, rescues cortical neurons from excitatory amino acid toxicity in culture. NeuroReport 1993;5:237-240.
38. Eshhar N, Streim S, Kohen R, Tirosh O, Biegon A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur J Pharmacol 1995;283:1-3.
39. Facci L, Dal-Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Scu USA 1995,92:3376-3380.
40. 3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995;73:907-910.
41. Feigenbaum JJ, Bergmann F, Richmond SA, et al. Non-psychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci USA 1989;86:9584-9587.
42. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993;90:7656-7660.
43. 2 receptors. Mol Pharmacol 1995;48:3.
44. Fontana A, Di Marzo V, Cadas H, Piomelli D. Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Prostag Leuk Ess Fatty Acids 1995;53:301-308.
45. Fride E, Barg J, Levy R, et al. Low doses of anandamides inhibit pharmacological effects of delta-9-tetra-hydrocannabinol. J Pharmacol Exp Ther 1995;272:699-707.
46. Fride E, Mechoulam R. Developmental aspects of anandamide: Ontogeny of response and effects of prenatal exposure to anandamide. Psychoneuroendocrinology 1996;21:157-172.
47. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993;231:313-314.
48. Fride E. Anandamides: Tolerance and cross-tolerance to delta(9)-tetrahydrocannabinol. Brain Res 1995;697:83-90.
49. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1647.
50. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991;279:129-134.
51. Giannikou P, Yiannakakis N, Fragkakis G, Probonas K, Wenger T. Anandamide (endogen cannabinoid) decreases serum prolactin level in pregnant rat. Neuroendocrinol Lett 1995;17:281-287.
52. Gill R, Foster AC, Woodruff GN. MK-801 is neuroprotective in gerbils when administered in the postischemic period. Neuroscience 1988;25:847-855.
53. Gill R, Foster AC, Woodruff GN. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in gerbil. J Neurosci 1987;7:3329-3343.
54. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993;36:3032-3034.
55. Holtzman D, Lovell RA, Jaffe JH, Freedman DX. Delta-9-tetrahydrocannabinol, neurochemical and behavioral effects in the mouse. Science 1969;163:1464-1467.
56. Howlett AC, Champion TM, Wilken GH, Mechoulam R. Stereochemical effects of 11-OH-delta-8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology 1990;29:161-165.
57. Howlett AC. Pharmacology of cannabinoid receptors. Ann Rev Pharmacol Toxicol 1995;35:607-634.
58. Howlett AC. Cannabinoid inhibition of adenylate cyclase, biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 1985;27:429-436.
59. Jacobs JA, Dellarco AJ, Manfredi RA, Harclerode J. The effects of delta-9-tetrahydrocannabinol, cannabidiol, and shock on plasma corticosterone in rats. J Pharm Pharmacol 1979;31:341-342.
60. Jarbe TUC, Hiltunen AJ, Mechoulam R. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-OH-delta-8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther 1989;250:1000-1005.
61. Jarho P, Uritti A, Jarvinen K, Pate DW, Jarvinen T. Hydroxypropyl-beta-cyclodextrin increases aqueous solubility and stability of anandamide. Life Sci 1996;58:181-185.
62. Johnson DE, Heald SL, Daily RD, Janis RA. Isolation, identification, and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostag Lenk Ess Fatty Acids 1993;48:429-437.
63. Johnson MR, Melvin LS. The discovery of nonclasical cannabinoid analgetics. in:. Mechoulam R, ed. Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press 1986:121-145.
64. Kubena RK, Peehack JC, Barry H. Corticosterone elevation mediated centrally by delta-1-tetrahydrocannabinol in rats. Eur J Pharmacol 1971;14:89-92.
65. Lee M, Yang KU, Kaminski NE. Effects of putative cannabinoid receptor ligands, anandamide, and 2-arachidonoyl-glycerol on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 1995;275:529-536.
66. Lichtman AH, Dimen KR, Martin BR. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 1995;119:282-290.
67. Little PJ, Compton DR, Mechoulam R, Martin B. Stereochemical effects of 11-OH-delta-8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 1989;32:661-666.
68. 18 neuroblastoma cells. Mol Pharmacol 1993;44:498-503.
69. Madden KP, Clark WM, Zivin JA. Delayed therapy of experimental ischemia with competitive N-methyl-d-aspartate antagonists in rabbits. Stroke 1993;24:1068-1071.
70. Maitre L, Waldmeir PC, Baumann PA. Effect of tetrahydrocannabinols on biosynthesis and utilization of catecholamines in the rat brain. Biochem Pharmacol Suppl 1974;2:845-850.
71. Mallet PE, Beninger RJ. The endogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behav Pharmacol 1996;7:276-284.
72. Maneuf YP, Corssman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 1996;22:382-385.
73. Martin BR, Thomas BF, Razdan RK. Structural requirements for cannabinoid receptor probes, in: Pertwee R, ed. Cannabinoid Receptors. London: Academic Press, 1995:35-79.
74. Martin BR. Cellular effects of cannabinoids. Pharmacol Rev 1986;38:45-74.
75. Matsuda LA, Bonner TI. Molecular biology of the cannabinoid receptor. in: Pertwee R, ed. Cannabinoid Receptors. London: Academic Press, 1995:117-140.
76. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
77. McLaughlin CR, Abood ME. Developmental expression of cannabinoid receptor mRNA. Dev Brain Res 1993;76:75-78.
78. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
79. Mechoulam R, Braun P, Gaoni Y. A stereospecific synthesis of (-)delta-1- and (-)delta-6-tetrahydrocannabinols. J Am Chem Soc 1967;89:4552-4554.
80. Mechoulam R, Devane WA, Glaser R. Cannabinoid geometry and biological activity, In: Murphy L, Bartke A, eds. Marijuana/Cannabinoids. Neurobiology and Neurophysiology. Boca Raton: CRC Press, 1992:1-33.
81. Mechoulam R, Feigenbaum JJ, Lander N, et al. Enantiomeric cannabinoids: Stereospecificity of psychotropic activity. Experientia 1988;44:762-764.
82. Mechoulam R, Fride E. The unpaved road to the endogenous brain cannabinoid ligands, the anandamides. in: Pertwee R, ed. Cannabinoid Receptors. London: Academic Press, 1995:233-258.
83. Mechoulam R, Hanus L, Martin BR. The search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 1994;48:1537-1544.
84. Mechoulam R, Lander N, Breuer A, Zahalka J. Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. Tetrahedron 1990;1:315-319.
85. Mcchoulam R. The pharmacohistory of Cannabis sativa. in: Mcchoulam R, ed. Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press, 1986:1-20.
86. Meldrum BS, Moncada C, Lekieffre D, Arvin B, Smith S. Strategies for cerebroprotection: Post-synaptic glutamate antagonism versus inhibition of ischemia induced glutamate release. In: Krieglstein J, Oberpichler-Schwenk H, eds. Pharmacology of Cerebral Ischemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1992:115-119.
87. Meldrum BS. Protection against neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc Brain Metab Rev 1990;2:27-57.
88. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
89. 45Ca] accumulation in rat brain alter closed head injury; attenuation by the novel neuroprotective agent HU-211. Brain Res 1995;685:1-11.
90. 45Ca] influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res 1993;622:79-85.
91. Nadler V, Mechoulam R, Sokolovsky M. The non-psychotropic-cannabinoid (+)-(3S,4S)-7-hydroxy-delta-6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett 1993;162:43-45.
92. Olney JW. Neurotoxicity of excitatory amino acids. In: McGeer EG, Olney JW, McGeer PL, eds. Kainic Acid as a Tool in Neurobiology. New York: Raven Press, 1978:37-70.
93. Ovadia H, Wohlman A, Mechoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Neuropharmacology 1995;34:175-180.
94. Ovadia H, Weidenfeld J. The involvement of the central adrenergic system in mediation of interleukin-1 induced fever, in: Bartfai T, Ottoson D, eds. Neuroimmunology of Fever. Oxford: Pergamon Press, 1992:37-44.
95. Pate DW, Jarvinen K, Urtti A, Jarho P, Jarvinen T. Ophthalmic arachidonoylethanolamide decreases intraocular pressure in normotensive rabbits. Current Eye Res 1995;14:791-797.
96. Pertwee RG, Stevenson LA, Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2, and anandamide. Br J Pharmacol 1993;110:1483-1490.
97. Pertwee RG. Effects of cannabinoids on thermoregulation: A brief review. In: Harvey DJ, Paton W, Nahas GG, eds. Marihuana'84. Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press, 1985;263-277.
98. Pertwee RG, ed. Cannabinoid Receptors. London: Academic Press 1995.
99. Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther 1988;36:189-261.
100. Puder M, Weidenfeld J, Chowers I, Nir I, Conforti N, Siegel RA. Corticotrophin and corticosterone secretion following delta-9-tetrahydrocannabinol in intact and hypothalamic deafferentated male rats. Exp Brain Res 1982;46:85.
101. Pulsinelli W, Sarokin A, Buchan A. Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia. In: Kogure K, Hossman K-A, Siesjo BK, eds. Progress in Brain Research. Amsterdam: Elsevier, 1993:125-135.
102. Razdan RK. The total synthesis of cannabinoids. In: J. A. Simon, ed. The Total Synthesis of Natural Products. New York: Wiley, 1981;185-262.
103. 2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats. Neuroendocrinology 1995;61:714-721.
104. Romero J, Garcia L, Cebeira M, Zadrozny D, Fernandez-Ruiz JJ, Ramos JA. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: Role of nigrostriatal dopaminergic neurons. Life Sci 1995;56:2033-2040.
105. Romero J, Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide or to delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav 1995;51:731-737.
106. Romero J, Garcia-Palomero E, Fernandez-Ruiz JJ, Ramos JA. Involvement of GABA(B) receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behav Pharmacol 1996;7:299-302.
107. Schildkraut JJ, Efron DH. Effect of delta-9-tetrahydrocannabinol on the metabolism of norcpinephrine in rat brain. Psychopharmacologia 1971;20:191-196.
108. Schmid HH, Schmid PC, Natarajan V. N-acylated glycero-phospholipids and their derivatives. Prog Lipid Res 1990;29:1-43.
109. Schmid PC, Krebsbach RJ, Perry SR, Dettmer TM, Maasson JL, Schmid HHO. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lettt 1995;375: 117-120.
110. Schuel H, Goldstein E, Mechoulani R, Zimmerman AM, Zimmerman S. Anandamide (arachidonoylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci USA 1994;91:7678-7682.
111. Schwarz H, Blanco FJ, Lotz M. Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 1994;55:107-115.
112. Shapira Y, Shohami E, Sidi A, Soffer D, Freeman S, Cotev S. Experimental closed head injury in rats: Mechanical, pathophysiologic and neurologic properties. Critical Care Med 1988;16:258-265.
113. Shapira Y, Artru A, Yadid G, Shohami E. Methyl-prednisolone does not decrease eicosanoid levels or edema in brain tissue or improve neurological outcome following head trauma in rats. J Anesth Analg 1992;75:238-244.
114. Shapira Y, Davidson E, Weidenfeld J, Cotev S, Shohami E. Dexamethasone and indomethacin do not affect brain edema following head injury in rats. J Cereb Blood Flow Metab 1988;8:395-402.
115. Shapira Y, Yadid G, Cotev S, Niska A, Shohami E. Protective effect of MK-801 in experimental brain injury. J Neurotrauma 1990;7:131-139.
116. 2+-chahnel. Eur J Pharmacol 1996;296:347-350.
117. Shintani F, Kanba S, Nakaki T, et al. Interleukin-1 augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 1993;13:3574-3581.
118. Shohami E, Bass R, Ben Hur T, Gallily R. Cytokine production in the brain following closed head injury: TNF-α inhibition is associated with cerebroprotection. Eur Cytokine Netw 1996;7:309.
119. Shohami E, Novikov M, Bass R. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res 1995;674:55-62.
120. Shohami E, Novikov M, Mechoulam R. A non-psychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury. J Neurotrauma 1993;10:109-119.
121. Slipetz DM, O'Neill GP, Favreau L, et al. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 1995;48:352-361.
122. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994;270:219-227.
123. Souilhac J, Poncelet M, Rinaldi-Carmona M, Le-Fur G, Soubrie P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 1995;51:3-7.
124. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoyl-glycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Comm 1995;215:89-97.
125. 2+-dependent transacylase and phosphodiesterase activities. Biochem Biophys Res Comm 1996;218:113-117.
126. 1 cannabinoid receptors. Naunyn Schmiedeberg's Arch Pharmacol 1995;352:576-579.
127. Varga K, Lake K, Martin BR, Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 1995;278:279-283.
128. Venance L, Piomelli D, Glowinski J, Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signaling in striatal astrocytes. Nature 1995;376:590-594.
129. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 1993;61:352-355.
130. Wartmann M, Campbell D, Subramanian A, Burstein SH, Davis RJ. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett 1995;359:133-136.
131. Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994;59:110-112.
132. Weidenfled J, Siegel RA, Conforti N, Feldman S, Chowers I. Site and mode of action in indomethacin on the hypothalamo-hypophyseal-adrenal axis: a temporal study in intact, hypothalamic deafferentated and hypothalamic lesioned male rats. Endocrinology 1981;109:205-209.
133. Welch SP, Dunlow LD, Patrick GS, Razdan RK. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: Blockade of delta-9-THC-induced antinociception. J Phamacol Exp Ther 1995;273:1235-1244.
134. Wenger T, Toth BE, Martin BR. Effects of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci 1995;56:2057-2063.
135. Wiley J, Balster R, Martin B. Discriminative stimulus effects of anandamide in rats. Eur J Pharmacol 1995;276:49-54.
136. Yoles E, Belkin M, Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J Neurotrauma 1995;13:49-57.